Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

about

Therapeutic efficacy of nanomedicines for prostate cancer: An update Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model.

P2860

Q26766305-B9177BD0-47FC-47AC-B092-B97F7763383F Q37194117-40EAED90-426F-46ED-8B3A-26907E2DE08D

P2860

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q38835047

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

@en

type

Item

label

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

@en

prefLabel

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

@en

P1476

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer

@en

P2093

Rhonda J Rosengren

http://www.w3.org/2001/XMLSchema#string

Tara Pritchard

http://www.w3.org/2001/XMLSchema#string

P2860

The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer

Global cancer statistics, 2012

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Therapeutic nanoparticles for drug delivery in cancer

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Increased survival with enzalutamide in prostate cancer after chemotherapy

Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.

The determination of raloxifene in rat tissue using HPLC.

P304

441-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/1061186X.2015.1086360

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sebastien Taurin

Khaled Greish

P577

2015-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26373825

http://www.w3.org/2001/XMLSchema#string

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

about

P2860

P2860

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698